On Wednesday, Following Stocks were among the “Top Priority Stocks” For Traders -Ironwood Pharmaceuticals, (NASDAQ:IRWD), ReneSola (NYSE:SOL), Proshares Trust II (NYSEARCA:SCO), Horizon Pharma (NASDAQ:HZNP)
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) & Exact Sciences Corp. (EXAS) divulged an agreement to co-promote Exact Sciences’ Cologuard®, the first and only FDA-approved noninvasive stool DNA screening test for colorectal cancer. The agreement provides for the near-term expansion of Cologuard promotional efforts through the use of Ironwood’s clinical sales specialists to more than double the number of physicians reached in the United States. The non-exclusive co-promotion agreement covers an initial one-year term with the opportunity for extension.
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) declined -6.27%, and closed at $15.10. The company has the market capitalization of $2.24 billion. The beta value of the stock is 1.40. On the other hand the stock’s volatility for the week is 5.52%, and for the month is 4.40%. The stock’s price to book ratio is $23.97, however price to sale ratio is $27.90. Analyst’s mean recommendation regarding this stock is 2.80. (Where 1=Buy, 5=Sale).
Ironwood Pharmaceuticals, Inc. (IRWD) offered an update on its 4th quarter 2014 and recent business activities. The company continued to make strong progress maximizing LINZESS, advancing its pipeline of investigational medicines and prioritizing investments within key growth drivers.
Formerly On March 11, 2015ReneSola Ltd. (ADR) (NYSE:SOL) a leading brand and technology provider of energy efficient products, stated that the European Commission has notified the Company regarding a potential compliance issue with the undertaking agreement, mainly due to the impracticality of monitoring the Company’s OEM producers and undertaking practice.
ReneSola Ltd. (ADR) (NYSE:SOL)’s shares picked down -7.50%, and closed at $1.48. The stock volatility for the week is 8.33%, while for the month remained 6.83%. The company holds consensus target price of $1.60.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.24 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -1.10% and Annual EPS growth for the past 5 years is considered as -27.00%.
The mean recommendation of analysts for this stock is 3.50. (Where 1=Buy, 5=Sale).
ReneSola Ltd. (ADR) (SOL) along with its subsidiaries manufactures and sells various solar power products. It works through two segments, Wafer, and Cell and Module. The company offers virgin polysilicon; mono crystalline and multi crystalline solar wafers; and photovoltaic cells. It also provides mono crystalline and multi crystalline solar modules for use in various residential, commercial, industrial, and other solar power generation systems. In addition, the company offers wafer processing services.
Proshares Trust II (NYSEARCA:SCO) decreased -6.84%, and closed at $83.20. The company holds the market capitalization of $278.56M. Its 20-day moving average decreased -0.45%, below 50-day moving average of -2.57%, below 200-day moving average of 64.97% from the latest market price of $83.20.
Horizon Pharma PLC (NASDAQ:HZNP) a specialty biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, disclosed its fourth quarter and full year 2014 financial results, Total net sales in the fourth quarter of 2014 were $103.8 million, compared with $30.1 million in the fourth quarter of 2013, representing 245 percent year over year growth. Total net sales for the full year 2014 were $297.0 million, compared with $74.0 million for the full year 2013, representing 301 percent year over year growth.
Horizon Pharma PLC (NASDAQ:HZNP) fell -6.47%, and closed at $20.59. The stock has the beta value of 2.36, and its volatility for the week is 4.45%, while for the month it is 4.23%. The company has the market capitalization of $2.70 Billion. The company holds the book value per share of 4.67, whereas cash per share is 1.75. Price to book ratio remained 4.41, while price to sale ratio is 8.67. Analysts mean recommendation for the stock is said to be 1.60 (where 1=Buy, 5=sale).
Horizon Pharma PLC (HZNP) a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and globally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
